We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 41.30 | 40.15 | 41.05 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 3.1M | -6.51M | -0.0217 | -18.99 | 123.89M |
By Michael Susin
Futura Medical PLC shares rose on Monday after it said it remains on track to submit its MED3000 erectile-dysfunction treatment to the U.S. drug regulator by the end of the third quarter of 2022.
Shares at 0900 GMT were up 3.30 pence, or 10%, at 34.90 pence.
The U.K. pharmaceutical developer focused on sexual health and pain relief said it is carrying out additional studies for the U.S. Food and Drug Administration as well as a short study about the ability of individuals to self-diagnose their erectile dysfunction and select the treatment correctly.
The company said it is aiming for an FDA authorization to sell MED3000 without a doctor's prescription in the first quarter of 2023, becoming the first ED treatment available over the counter.
"We are continuing to make good progress with the regulatory process for MED3000 in the U.S. We are also executing upon our strategic plans to leverage commercialization globally with a network of licensing and distribution partners with brand-building strength, healthcare credibility and regional infrastructure and marketing expertise," Chief Executive James Barder said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
December 20, 2021 04:40 ET (09:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Futura Medical Chart |
1 Month Futura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions